Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...
Integrating GLP-1 therapy into primary care enables clinicians to contextualize weight loss alongside cardiometabolic ...
In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weight management program, and a new report highlights ...
IV fluids like normal saline, dextrose, and sterile water are the most systemically dangerous shortages on the list, as they ...
In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...
In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected ...
Documented AI productivity gains include 28% faster target identification, 22% faster biomarker identification, and 20% ...
Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
CEO of MaxCyte, discusses the need for developers to come together with platforms. Advertisement. Latest Updated Articles. Advertisement ...
Adjusted EPS was $7.23, materially ahead of expectations, and 2026 adjusted EPS guidance was raised to >$18.25, aided by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results